The risk of lung cancer drops substantially within five years of quitting, according to a new analysis of the landmark Framingham Heart Study by researchers at Vanderbilt University Medical Center.
News: May, 2018
For the 10th year in a row Vanderbilt University Medical Center (VUMC) and Vanderbilt-Ingram Cancer Center (VICC) have been named a CEO Cancer Gold Standard employer by the CEO Roundtable on Cancer.
Jordan Berlin, MD, has been named associate director of Clinical Investigation Strategy and Shared Resources at Vanderbilt-Ingram Cancer Center (VICC). In his new role he will chair the Resource Allocation Committee and continue as chair of the Clinical Trials Shared Resource (CTSR) Steering Committee.
A new technology may allow doctors to better distinguish benign from malignant lung nodules in CT-based lung cancer screening.
Ben Ho Park, MD, PhD, has been named co-leader of the Breast Cancer Research Program, director of Precision Oncology and associate director for Translational Research at Vanderbilt-Ingram Cancer Center. He will assume his new post Sept. 1.
Feeling Good in Your Own Skin is a free educational event for patients, caregivers and survivors to learn about advancements in melanoma research, clinical care, and survivorship.
Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer.
This year’s Vanderbilt-Ingram Cancer Center (VICC) Annual Scientific Retreat focused on the association between cancer development, the immune system and the microbiome, which includes all of the microorganisms and the genetic material of these microorganisms in the human body and the surrounding environment.
Using four large-scale data sets from normal and cancerous breast tissue samples, Vanderbilt researchers have identified 101 candidate breast cancer susceptibility genes with variant-associated gene expression changes.
Vanderbilt researchers have developed a new process that can rapidly and inexpensively identify personalized cancer drugs derived from nature.